A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Exclusion Criteria

• •1. Individual with known or suspected uncontrolled central nervous system (CNS) metastases
• •2. Individual with history of carcinomatous meningitis
• •3. Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
• •4. Individual with evidence of corneal keratopathy or history of cornea transplant
• •5. Any serious unresolved toxicities from prior therapy
• •6. Significant cardiovascular disease
• •7. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
• •8. History of pneumonitis/interstitial lung disease
• •9. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention